TABLE II.
Predictors of Recurrence Free Survival (RFS) for Patients With Adrena Cortical Carcinoma Who Underwent Surgical Resection
| Univariate analysis
|
Multivariate analysis
|
|||
|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Gender | 0.652 | |||
| Female | Ref. | |||
| Male | 1.14 (0.62–2.11) | |||
| Age | 0.950 | |||
| <50 years | Ref. | |||
| ≥50 years | 1.00 (0.98–1.08) | |||
| ASA physical status | 0.132 | |||
| 1–2 | Ref. | |||
| 3–4 | 1.83 (0.83–4.03) | |||
| Coronary artery disease | 0.557 | |||
| No | Ref. | |||
| Yes | 1.32 (0.51–3.43) | |||
| Chronic heart failure | 0.498 | |||
| No | Ref. | |||
| Yes | 0.19 (0.03–1.36) | |||
| Chronic obstructive pulmonary disease | 0.147 | |||
| No | Ref. | |||
| Yes | 2.17 (0.76–6.22) | |||
| Chronic renal insufficiency | 0.052 | |||
| No | Ref. | |||
| Yes | 4.33 (0.98–18.9) | |||
| Diabetes mellitus | 0.268 | |||
| No | Ref. | |||
| Yes | 1.59 (0.69–3.61) | |||
| Incidentaloma | 0.270 | |||
| No | Ref. | |||
| Yes | 0.72 (0.39–1.29) | |||
| Functional status | 0.050 | 0.075 | ||
| No | Ref. | Ref. | ||
| Yes | 1.84 (1.00–3.38) | 1.74 (0.95–3.20) | ||
| Tumor size | 0.242 | |||
| ≤5 cm | Ref. | |||
| >5 cm | 1.15 (0.91–1.45) | |||
| Preoperative chemo-radiotherapy | 0.705 | |||
| No | Ref. | |||
| Yes | 0.68 (0.09–4.90) | |||
| Other organ resected | 0.118 | |||
| No | Ref. | |||
| Yes | 1.59 (0.88–2.87) | |||
| IVC exclusion | 0.110 | |||
| No | Ref. | |||
| Yes | 2.05 (0.84–4.95) | |||
| AJCC tumor Status | 0.002 | 0.022 | ||
| T stages I–II | Ref. | Ref. | ||
| T stages III–IV | 2.67 (1.41–5.03) | 2.09 (1.11–3.94) | ||
| AJCC node status | 0.027 | |||
| N0 | Ref. | |||
| N1 | 1.50 (1.04–2.15) | |||
| AJCC metastasis status | 0.011 | 0.061 | ||
| M0 | Ref. | Ref. | ||
| M1 | 2.58 (1.24–5.38) | 2.04 (0.97–4.29) | ||
| Margin status | 0.100 | |||
| R0 | Ref. | |||
| R1/R2 | 1.68 (0.90–3.16) | |||
| Complications | 0.049 | |||
| No | Ref. | |||
| Yes | 1.87 (1.00–3.51) | |||
| Readmission within 90 days | 0.090 | |||
| No | Ref. | |||
| Yes | 1.75 (0.91–3.35) | |||
| NLR | 0.022 | |||
| ≤5 | Ref. | |||
| >5 | 1.99 (1.10–3.59) | |||
| PLR | 0.021 | 0.067 | ||
| ≤190 | Ref. | Ref. | ||
| >190 | 1.93 (1.11–3.38) | 1.72 (0.96–3.09) | ||
| Post-operative chemotherapy | 0.630 | |||
| Not performed | Ref. | |||
| Performed | 0.79 (0.21–2.02) | |||
| Post-operative radiotherapy | 0.748 | |||
| Not performed | Ref. | |||
| Performed | 0.84 (0.30–2.37) | |||
| Post-operative chemotherapy with mitotane | 0.220 | |||
| Not performed | Ref. | |||
| Performed | 1.45 (0.79–2.64) | |||
ASA, American Society of Anesthesiologist; IVC, inferior vena cava; P-values ≤ 0.05 are reported in bold and indicate statistically significant results.